At Johnson & Johnson, we are guided in all that we do by the values established in Our Credo. This foundational document states clearly that we must provide an inclusive work environment where we respect the dignity and diversity of each individual and recognize their merit.
Our annual Diversity, Equity & Inclusion Impact Review demonstrates how we hold ourselves accountable to our long-standing commitment to building a company—and a world—where we all belong.
The stories in the 2022 Review highlight the impact of data-driven strategies that accelerate DEI outcomes. Having a workforce comprised of individuals with different perspectives, abilities, backgrounds, and experiences is critical to advancing health equity and improving access to care for underserved communities, both in the U.S. and around the world.
I’m proud of what we accomplished in 2022 as we continued to advance our DEI imperatives. To name a few highlights:
- We achieved an important Health for Humanity DEI goal with 36 percent of our management positions in the U.S. held by ethnically and racially diverse employees. In addition, women made up 53.8 percent of new hires globally.
- We advanced our $100 million Our Race to Health Equity initiative that aims to help close the racial health gap in the U.S. through efforts around clinical trial diversity, upskilling health workers, fellowships and scholarships, pilots, and interventions.
- Around the world, we spent $3.2 billion with Tier 1 diverse suppliers and $650 million with Tier 2 diverse suppliers, ensuring we create wealth and opportunity across a vast network of partners.
As we enter a new era with Johnson & Johnson dedicated to Pharmaceutical and MedTech, DEI will continue to play a central role in how we accelerate innovation and improve outcomes for the communities we serve.
I hope you are encouraged by what we’ve achieved and inspired by what’s possible when we act with a sense of belonging and a shared purpose of improving health for humanity.
